

## CURRICULUM VITAE

### JOHN CHARIN SOMBERG, M.D.

- Born:** .....
- 1966:** .....
- 1970:** A.B. New York University College of Arts & Sciences, Heights Center, Bronx, New York
- 1974:** MD New York Medical College, New York
- 1974-75:** Medical Intern, New York Medical College, NYC, NY
- 1975-76:** Medical Junior Resident, New York Medical College, Department of Medicine, NYC, NY
- 1976-77:** Chief Medical Resident, New York Medical College
- 1977-79:** Fellow Cardiovascular Medicine, Peter Bent Brigham Hospital, Harvard Medical School, Boston, MA
- 1979-80:** Instructor of Medicine, Peter Bent Brigham Hospital, Harvard Medical School, Boston, MA
- 1980-85:** Assistant Professor of Medicine and Pharmacology Albert Einstein College of Medicine, Bronx, NY Director Cardia, Arrhythmia and Clinical Electrophysiology Service, Hospital of the Albert Einstein College of Medicine
- 1985-88:** Associate Professor of Medicine & Pharmacology. Albert Einstein College of Medicine. Director, Cardiac Arrhythmia & Clinical Electrophysiology Service
- 1985-94:** Editor - Journal of Clinical Pharmacology
- 1988-89:** Associate Professor of Medicine & Pharmacology Associate Chief of Cardiology, Chief, Division Clinical Pharmacology, Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL
- 1989-98:** Professor of Medicine and Pharmacology Chief, Division of Cardiology; Chief, Division of Clinical Pharmacology, Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL
- 1998 to Present:** Chief, The Division of Clinical Pharmacology, Professor of Medicine and Pharmacology, Rush University Medical College. Rush Presbyterian-St. Luke's Medical Center, Chicago, IL
- 1994 to Present:** Editor - American Journal of Therapeutics®
- 2003** Adjunct Professor of Medicine, Cornell University, Weill Medical College

**Memberships:**

American Heart Association Council on Basic Science and Clinical Cardiology

Federation for the Advancement of Science Experimental Biology

American Federation of Clinical Research

Chicago Chapter, American Heart Association

Board of Governors, American Heart Association of Metro Chicago

Fellow, American College Of Clinical Pharmacology

Regent, American College of Clinical Pharmacology

Board Certification, Clinical Pharmacology, 1991

**Licenses:**

1975 - Medical License New York State

1975 - Certification by National Board of Medical Examiners

1977 - Massachusetts Medical License

1988 - Illinois Medical License

**Honors:**

1970 - Outstanding Student Researcher Award  
New York University

1974 - Frank C. Pollack, MD Award for Unusual Excellence in  
Medical Research, New York Medical College

1980 - Established Investigator American Heart Association

1985 - Regent, American College of Clinical Pharmacology

1991 - Distinguished Service Award, American College of  
Clinical Pharmacology

1991 - Re-elected third term Regent, American College of  
Clinical Pharmacology, 1991-1996

**Research Training:**

1967-69: Physiology Technician, New York University

1969-70: Research Associate, NYU Behavioral Physiology Section

1971-74: Student Researcher, New York Medical College Division of Cardiology, New York Medical College

1975-77: Director of Animal Research Laboratories Division of Cardiology, New York Medical College

1977-79: Research Fellow in Medicine, Harvard Medical School

**Editorial Board Memberships:**

Journal of Clinical Pharmacology

American Journal of Cardiology

Forum Medicum: Drug Therapy for the 90's Clinical Pharmacology:  
Therapy & Toxicity

**Journal Reviewer:**

American Heart Journal

American Journal of Cardiology

The American Journal of Managed Care

**Previously Reviewed for:**

Critical Care Medicine

New England Journal of Medicine

Annals of Internal Medicine

Circulation

Life Sciences

**Editor:**

Journal of Clinical Pharmacology  
1982 – 1994

American Journal of Therapeutics  
1994 - present

## **Book Chapters:**

1. Somberg, JC: Clinical Use of Class Ic Antiarrhythmic Drugs. In: Antiarrhythmic Drugs; E.M. Vaughan Williams. Springer-Verlag; New York, 1989.
2. Somberg, JC: Cifenaline in Current Cardiovascular Drug Therapy. W.B. Saunders 1989.
3. Somberg, JC: Tocainide in Current Cardiovascular Drug Therapy. W.B. Saunders 1989.
4. Somberg JC, Kraemer J, Zevitz M: Acute Pharmacologic Therapy of Cardiac Arrhythmias in Emergency Medicine. W.B. Saunders 1989.
5. Somberg JC, Zevitz M: The Pharmacology of Antiarrhythmic Drug Therapy. Principles and Practices of Emergency Medicine, 1990.
6. Somberg, JC, Colucci R: The Treatment of Cardiac Arrhythmias in Essentials of Critical Care; Pharmacology Ed Bart Chernow, Williams and Wilkins; 1994.
7. Colucci R, Somberg JC: The Treatment of Cardiac Arrhythmias. Chernow: The Pharmacologic Approach to the Critically Ill Patient, Second Edition, 1992.
8. Colucci R, Somberg JC: Essentials of Critical Care Pharmacology. B. Chernow: The Pharmacology Approach to the Critically Ill Patient, Third Edition, 1994, pp 313-337.
9. Somberg JC: The Evolving Drug Discovery and Development Process. Marcel Dekker, Inc. New York, NY 1996.
10. Somberg JC, Molnar J: Atrial Fibrillation and Valve Disease. In - Borer JS, Isom OW (eds): Pathophysiology, Evaluation and Management of Valvular Heart Diseases. Adv Cardiol. Basel, Karger, 2002, vol 39, pp 39-48.

## **BOOKS:**

1. Vaughan-Williams M, Somberg JC: Control of Cardiac Rhythm. Lippincott-Raven, Philadelphia, PA 1997.
2. Borer J, Somberg JC: Cardiovascular Drug Development. Marcel-Dekker, Inc., New York, NY 1997.
3. Somberg JC: Contemporary Diagnosis and Management of Cardiac Arrhythmias, Handbooks in Health Care. Newton, PA 2000.

## **SYMPOSIA CHAIRED:**

1. New Antiarrhythmic Agents; American College of Clinical Pharmacology Meeting, 1980.
2. New Antiarrhythmic Agents in the Prevention of Ventricular Tachycardia; American Heart Association Meeting, 1982.

3. Drug Interactions of Clinical Importance; American College of Cardiology Annual Scientific Session, 1983.
4. QT Prolongation; Antiarrhythmic or Pro-arrhythmic; American College of Cardiology, 1984.
5. New Antiarrhythmic Drugs; American College of Cardiology, 1984.
6. Neural Excitatory Effects of Digitalis: 200 Years; Symposium held at Albert Einstein College of Medicine, 1985.
7. Pharmacology of Antiarrhythmic Drugs; American College of Cardiology, 1989.
8. Clinical Model for Antihypertensive Therapy in the 90's; American Heart Association, 1990.
9. The Development of Antiarrhythmic Agents; American College of Clinical Pharmacology Annual Meeting, 1990.
10. Pharmacologic Agents and Congestive Heart Failure; American College of Cardiology, 1991.
11. Intensive Board Review Course, American College of Clinical Pharmacology, 1992.
12. Intensive Board Review Course, American College of Clinical Pharmacology, 1993.
13. Intensive Board Review Course in conjunction with American Journal of Therapeutics, Chicago Medical School, 1994.
14. Advances in Cardiovascular Pharmacology & Protocol Design and Methodology - Annual Meeting, 1980 to present. (Annual Meeting)
15. International Symposia on Cardiovascular Drug Development, 1990 to 1998.

#### **PHARMACEUTICAL STUDIES:**

1. The Anti-Anginal Effects of Propranolol: A Continued Multi-Center Study - Ayerst Laboratories.
2. The Antiarrhythmic Effects of Lorainide at Electrophysiologic Testing - Janssen Pharmaceuticals.
3. The Antiarrhythmic Effects of Cibenzoline Determined at Electrophysiologic Testing – Hoffman LaRoche Laboratories.
4. Dose Finding Study for VPC Suppression by Cibenzoline - Hoffman LaRoche Laboratories.
5. VPC Suppression with Cibenzoline: A Multi-Center Randomized Controlled Study - Hoffman LaRoche Laboratories.
6. The Antiarrhythmic Efficacy of Bethanidine in the PES Laboratory – A.H. Robbins Pharmaceuticals.

7. The Electrophysiologic Effects of Lidoflazine in Man - Janssen Pharmaceuticals.
8. The Electrophysiologic and Antiarrhythmic Action of Bepridil in Man - McNeil Pharmaceuticals.
9. The Evaluation of a Possible Interaction of Bepridil and Digoxin in Man – McNeil Pharmaceuticals.
10. The Effects of Lorcaïnide on VPC Suppression in Man - Janssen Pharmaceuticals.
11. The Effect of Lorcaïnide, Lidocaine or Procainamide in Patients with Inducible Ventricular Tachycardia Post MI - Janssen Pharmaceuticals.
12. The Antiarrhythmic Effects of Bepridil: A Multi-Center Randomized Controlled Trial – McNeil Pharmaceuticals.
13. The Effects of Labetolol on Autonomic Function in Man - Schering Plough Corporation.
14. The Comparative Efficacy of Encainide and Quinidine in the Electrophysiology Laboratory in Patients with Inducible Ventricular Tachycardia – Bristol Myers Laboratories.
15. The Antiarrhythmic Effects of Ethmozine in Patients with Inducible Ventricular Tachycardia - DuPont Pharmaceuticals.
16. The Efficacy of Ethmozine in Suppression of VPC Frequency and Complex Arrhythmias - DuPont Pharmaceuticals.
17. The Antiarrhythmic Efficacy of IV Amiodarone in Patients with a Cardiac Arrest – Ives Laboratory.
18. The Effects of Tocainide Compared to Lidocaine in Prophylaxis of Arrhythmias Post MI – Merck Sharp & Dohme Laboratories.
19. A Randomized Parallel Controlled Trial of Cibenzoline versus Quinidine in the Prevention of Atrial Fibrillation or Atrial Flutter - Hoffman LaRoche Laboratories.
20. Ezmolol for the Treatment of Unstable Angina - American Critical Care.
21. Flestolol for the Control of the Ventricular Response in Patients with Atrial Fibrillation or Atrial Flutter - DuPont Critical Care.
22. The Antiarrhythmic Effects of D-Sotolol at PES - Bristol Myers Laboratories.
23. The Comparative Effects of Sotolol and Procainamide in Patients with Ventricular Tachycardia at Electrophysiologic Testing - Bristol Myers Laboratories.
24. The Efficacy of Sotolol in Suppressing VPC Frequency Bristol Myers Laboratories.
25. The Efficacy of Indecainide as Contrasted to Procainamide in Patients with Sustained Ventricular Tachycardia - Eli Lilly Laboratories.

26. The Comparison of IV versus Oral Flecainide, in Patients with Ventricular Tachycardia at Electrophysiologic Testing - Riker 3M Pharmaceuticals.
27. A Randomized Placebo Controlled Trial of Sotalol for the Suppression of PVC's, Complex Arrhythmias and Non-sustained Ventricular Tachycardia – Bristol Myers Pharmaceuticals.
28. The Electrophysiologic Effects of Isradipine - Sandoz Pharmaceuticals.
29. The Efficacy of Adenosine in the Treatment of SVT: A Multi-Center Randomized Controlled Trial - Medco Research.
30. The Comparative Effects of IV Adenosine and Dipyridmole in Thallium Imaging – Astra Pharmaceuticals.
31. A Comparison of the Efficacy of Propafenone to Procainamide in Patients with Ventricular Tachycardia in the Electrophysiologic Laboratory – Knoll Pharmaceuticals.
32. The Efficacy of UK68,798 in Patients with Atrial Flutter or Fibrillation – Pfizer Pharmaceuticals.
33. The Anti-Anginal Efficacy of Betaxolol, A Placebo Controlled Randomized Study – Lorex Pharmaceuticals.
34. The Efficacy of Ramapril in Patients with Mild to Moderate Congestive Heart Failure – Hoechst Roussel Pharmaceuticals.
35. The Antihypertensive Effects of Terazosin in Hypertensive Patients: A Multi-Center Randomized Placebo Controlled Trial - Abbott Laboratories.
36. The efficacy of Quinapril in Patients with Congestive Heart Failure – Parke-Davis/Werner Lambert Company.
37. A Comparison of a Twice-a-Day Preparation of Procainamide with Procan SR in Patients with Frequent VPC's - Parke Davis Pharmaceuticals.
38. A Multi-Center Randomized Withdrawal of Lisinopril in Patients with Congestive Heart Failure - ICI Pharmaceuticals.
39. The Comparative Efficacy of Digoxin to ACE Inhibitors in Patients with Moderate Congestive Heart Failure - Burroughs Welcome Company.
40. The Anti-Anginal Efficacy of a New Topical Nitrate Preparation Determined by Exercise Testing - Ciba-Geigy Corporation.
41. The Anti-Anginal Efficacy of Isosorbide-5 Mononitrate in Patients with Exercise Induced Angina - Schering Plough Corporation.

42. A Study Investigating Safety and Duration of Effects of Isosorbide-5 -Mononitrate in a Controlled-Release Formulation in Patients with Stable Effort Angina Pectoris – Schering Plough Corporation.
43. A randomized trial of N-acetyl procainamide (NAPA) for the treatment of paroxysmal supraventricular arrhythmias (SVA-s) - Medco Pharmaceuticals.
44. A multicenter pilot study to assess safety and efficacy of Monoket® in patients with chronic stable angina pectoris - Schwarz Pharma.
45. Development of procedure to induce myocardial ischemia in patients with coronary artery disease via mental stress.
46. Protocol for the evaluation of topical nicotine preparations and optimal delivery.
47. A long-term (one-year) open-label, multicenter extension study of twice daily oral SK&F 108566 in patients with essential hypertension who have completed a clinical trial with SK&F 108566 - SmithKline Beecham Pharmaceuticals.
49. A 4-week, double blind parallel, placebo controlled, multicenter, trial of oral SK&F 108566 added to hydrochlorothiazide therapy in patients with essential hypertension – SmithKline Beecham Pharmaceuticals.
50. A dose response study of the safety and efficacy of Diltiazem once-daily extended release in the treatment of chronic stable exercise-induced angina pectoris – Hoechst-Roussel Pharmaceuticals Inc.
51. A Triple-Blind, Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy - Merck & Co., Inc.
52. Clinical Protocol for Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) - G.D. Searle & Company.
53. Omapatrilat Cardiovascular Treatment Assessment vs. Evalapril (Octave) - Bristol Meyers Squibb.

#### **PRE-CLINICAL PHARMACEUTICAL STUDIES**

1. The Efficacy of Bethanidine With and Without Protriptyline in a Dog Model of Ventricular Tachycardia - A.H. Robbins Company.
2. The Efficacy of Lorcainide in a Dog Model of Ventricular Tachycardia – Janssen Pharmaceuticals.
3. The Efficacy of Cibenzoline in a Dog Model of Ventricular Tachycardia - Hoffman LaRoche Laboratories.
4. An Evaluation of the Antiarrhythmic Properties of Sulfinpyrazone -



Ciba Geigy Corporation.

5. An Evaluation of the Electrophysiologic Effects of Lidoflazine Using Programmed Electrical Stimulation in the Dog - Janssen Pharmaceuticals.
6. The Antiarrhythmic Effects of Metoclopramide - A.H. Robbins Laboratories.
7. The Antiarrhythmic and Possible Pro-arrhythmic Effects of Bepridil in the Dog – McNeil Laboratories.
8. The Heparin-Nitroglycerin Interaction and the Evaluation of Hirulog® in Combination with IV Nitroglycerin - Biogen, Inc.

#### **CONSULTING POSITIONS WITH INDUSTRY**

1. Hoffman LaRoche - Cibenzoline Program
2. Janssen Pharmaceuticals - Lorcaïnide and Cardiovascular Development Program
3. McNeil Pharmaceuticals - Beprilil Program; Created Anti-Anginal Development Plan
4. Medco Research - Adenosine and NAPA Development Program
5. Forrest Laboratories - Consultant
6. Solvay Pharmaceuticals - Consultant. Tedisamil Program
7. Proctor & Gamble Pharmaceuticals - Consultant.

#### **COURSES DEVELOPED**

1. Advances in Cardiovascular Pharmacology: Protocol Design and Methodology; Founded course and directed for past 22 years in Washington, D.C.
2. International Symposium of Drug Development: Protocol Design and Methodology: Founded course and directed it jointly with Dr. Jeffrey Borer for eight years.
3. Clinical Updates Program Department of Medicine, 1993-1994.

#### **GRANTS**

1. Studies on the Cardiotoxicity of the Cardiac Glycosides NIH Training Grant 1977-79; NIH Recipient.
2. Studies on the Neurally Mediated Arrhythmogenic Effects of the Cardiac Glycosides - Established Investigator; American Heart Association, 1979-84.
3. The Evaluation of the Neurally Mediated Effects of Oubain in the Cat - NIH 1980-83; Principal Investigator.

4. Established Investigator, American Heart Association, 1982-1985.
5. Studies on Atrial Fibrillation and Risk for Sudden Death, Jansen Research, 1983-1985.
6. The Antiarrhythmic Effect of Amiodarone in Patients with Congestive Heart Failure – Co-Principal Site Investigator, VA Cooperative Study, 1990.
7. Adenosine Testing in Angina, Astra Sponsorship, 1989-1990.
8. Biogen Sponsored Study on the Heparin-Nitroglycerin interaction, 1993-1995.

#### **ABSTRACTS:**

- A1. Cagin N, Somberg J, Bounous H, Mittag T, Raines A, Levitt B. The influence of spinal cord transection on the tissue content of ouabain (H3) associated with ventricular fibrillation in the cat. *Fed Proc* 31:584, 1972.
- A2. Freeman E, Cagin N, Somberg J, Mittag T, Levitt B. Propranolol inhibition of ouabain uptake in the isolated guinea pig heart. *Fed Proc* 32:718, 1973.
- A3. Szabo A, Somberg J, Levitt B. Potentiation of ouabain cardio-toxicity by insulin on the perfused guinea pig heart. *Diabetes* 23 (Suppl 1): 353, 1973.
- A4. Cagin N, Freeman E, Somberg J, Bounous H, Raines A, Levitt B. Failure of dose to reflect toxic myocardial ouabain content in the cat. *Fed Proc* 34:746, 1975.
- A5. Somberg J, Bounous H, Cagin N, Levitt B. The protection prostaglandin E1 and E2 afford against ouabain induced cardio-toxicity. 7th European Congress of Cardiology, June 1976, Abstract Book I, 640.
- A6. Somberg J, Bounous H, Cagin N, Levitt B. Prostaglandin protection against ouabain induced cardiotoxicity. *Advances in Prostaglandin and Thromboxane Research*, Vol 2, B. Samuelson and R. Paoletti (eds.), Raven Press, 1976.
- A7. Somberg J, Cagin N, Levitt B, Kleid J, Levi R, Gerrity M, Bounous H. The influence of histamine H2 receptor antagonists on ouabain cardiotoxicity in the cat. *Am J Cardiol* 39:275, 1977.
- A8. Somberg J, Bounous H, Cagin N, Levitt B. The protection prostaglandin E1 and E2 afford against ouabain-induced toxicity in the cat. *Bull NY Acad Med* 53:3, 1977.
- A9. Somberg J, Cagin N, Levitt B. Inhibition of myocardial adriamycin uptake. *Fed Proc* 36:303, 1977.
- A10. Risler T, Somberg J, Blute R, Smith T. The influence of renal arterial pressure on excretion of digoxin. *Fed Proc* 37:913, 1978.

- A11. Somberg J, Risler T, Smith T. Effects of toxic doses of ouabain on myocardial cation transport in neurally intact and in spinally transected cats. *Fed Proc* 37:913, 1978.
- A12. Somberg J, Cagin N, Levitt B, Leonard D, Bounous H. Histamine antagonists as antiarrhythmic drugs. *Bull NY Acad Med* 54:334, 1978.
- A13. Risler T, Somberg J, Blute R, Smith T. The effects of renal artery constriction on digoxin clearance. *Clin Res* 26:594, 1978.
- A14. Somberg J, Risler T, Smith T. Studies on the toxicity of charged digitalis derivative. 7th International Congress of Pharmacology, Paris, Abstracts, 734, 1978.
- A15. Somberg J, Mudge G, Smith T. The therapeutic and toxic effects of charged digitalis derivatives. *Circulation* 58 (Suppl II): 4, 22, 1978.
- A16. Somberg J, Smith T. Localization of the neurally mediated arrhythmogenic properties of digitalis. *Circulation* 58 (Suppl II): 4, 145, 1978.
- A17. Kuhlman J, Somberg J, Smith T. Localization of the neurally mediated coronary vasoconstrictor properties of digitalis. *Clin Res* 27:2, 181A, 1979.
- A18. Risler T, Somberg J, Smith T. Die bedeutung des renal artiellen druckes fur die digoxin clearance. *Nieven und Hochdruckkrankheiten* 5:243, 1979.
- A19. Somberg J, Barry W, Smith T. Relative sensitivity of Purkinje fibres and myocardium to the effects of digitalis. *Circulation* 59 (Suppl II): 210, 1979.
- A20. Somberg J, Miura DS, Smith T. Cardiac arrhythmogenic effects of electrical stimulation of the area postrema. *Clin Res* 28:213A, 1980.
- A21. Somberg J, Miura DS. Augmentation of digitalis induced arrhythmia by area postrema stimulation. *Circulation* 62:985, 1980.
- A22. Somberg J, Knox S, Miura DS. Quinidine-digitalis interaction: Effect of cardiac Purkinje fibers and myocardium. *Circulation* 62:985, 1980.
- A23. Somberg J, Knox S. The antiarrhythmic effects of metoclopramide. *Circulation* 62:664, 1980.
- A24. Somberg J, Knox S. The antiarrhythmic effects of sulfinpyrazone. *Circulation* 62:300, 1980.
- A25. Risler T, Somberg J, Smith T. Die bedeutung methodischer unterschiede fur die messung der renalen digoxin clearance. *German F Cardiol (Zeitschrift fur)* 70:4, 290, 1981.
- A26. Somberg J, Willens H, Camilleri W, Maguire W, Miura DS. Effect of Lorcaïnide on suppressing ventricular tachycardia induced by programmed stimulation. *Circulation* 64:4, 37, 1981.
- A27. Somberg JC, Nosta JJ, Knox S. Localization of the neurally mediated facilitation of post infarction arrhythmias. *Circulation* 64:4, 140, 1981.

- A28. Somberg JC, Willens H, Maguire W, Miura DS. Verapamil-Digitalis Interaction: Effects on cardiac Purkinje fibers and myocardium. *Am J Cardiol* 49:1025, 1982.
- A29. Knapp AB, Maguire W, Karen G, Karmen A, Miura DS, Somberg JC. The Effect of Cimetidine administration on serum Lidocaine levels in man. *Am J Cardiol* 49:1026, 1982.
- A30. Levitt B, Factor S, Somberg JC. Digitoxin blockade of Adriamycin cardiotoxicity in the rabbit. *Am J Cardiol* 49:985, 1982.
- A31. Karen G, Tepper D, Butler B, Levitt B, Miura DS, Somberg JC. Atrial fibrillation increases myocardial vulnerability of ventricular arrhythmia induction. *Clin Res* 30:2, 196A, 1982.
- A32. Keren G, Aogaichi A, Somberg JC, Miura DS. Effects of Cibenzoline on ventricular tachycardia induced by programmed electrical stimulation in the dog. *Clin Res* 30:2, 633A, 1982.
- A33. Somberg JC, Willins H, Keren G, Miura DS. A new animal model for the electrophysiologic testing of antiarrhythmic drugs. *Fed Proc* 41:5, 1711, 1982.
- A34. Knapp AB, Maguire W, Keren G, Karmen A, Levitt B, Miura DS, Somberg JC. The effect of Cimetidine and Diphenhydramine on serum Lidocaine levels in man. *Gastro* 82:5, 1102, 1982.
- A35. Dangman K, Somberg JC, Miura DS. Electrophysiologic effects of Bethanidine Sulfate on canine cardiac Purkinje fibers. *Circulation* 66:II:130, 1982.
- A36. Butler B, Somberg JC, Miura DS, Levitt B. Atrial fibrillation increases myocardial sensitivity to digitalis toxicity. *Circulation* 66:II:57, 1982.
- A37. Keren G, Somberg JC, Miura DS. Transient burst entrainment for interruption of ventricular tachycardia. *Clin Res* 31:2, 195A, 1983.
- A38. Miura DS, Keren G, Tepper D, Willens H, Somberg JC. Effects of lidoflazine on myocardial vulnerability. *Clin Res* 31:2, 206A, 1983.
- A39. Keren G, Tepper D, Scharf M, Kleinbaum H, Levitt B, Miura DS, Somberg JC. The enhancement of myocardial vulnerability by atrial fibrillation. *Fed Proc* 42:4, 4816, 1983.
- A40. Somberg JC. The antiarrhythmic effects of Metoclopramide in post infarction arrhythmias. *Fed Proc* 42:5, 1289, 1983.
- A41. Tepper D, Butler B, Keren G, Somberg JC, Taragin M, Siegel L, Aogaichi K, Miura DS. Effects of oral cibenzoline therapy on ventricular ectopic activity. *Clin Res* 31:2, 634A, 1983.
- A42. Siegel L, Keren G, Torres V, Miura DS, Somberg JC. Antiarrhythmic action of Verapamil in preventing programmed stimulation induced ventricular tachycardia. *Clin Res* 31:2, 633A, 1983.

- A43. Raghaven N, Scharf M, Keren G, Butler B, Wiener D, Miura DS, Somberg JC. The antiarrhythmic action of Bepridil in preventing PES induced VT in dogs. *Clin Res* 31:2, 632A, 1983.
- A44. Taragin M, Tepper D, Butler B, Torres V, Keren G, Miura DS, Somberg JC. Single daily dose of Lorcaïnide for chronic prophylaxis of ventricular tachycardia. *Clin Res* 31:2, 634A, 1983.
- A45. Keren G, Kleinbaum H, Tepper D, Butler B, Dangman K, Miura DS, Somberg JC. The antiarrhythmic effects of Bethanidine. *Clin Res* 31:2, 629A, 1983.
- A46. Willens H, Goldberg D, Gross T, Tepper D, Butler B, Torres V, Miura DS, Somberg JC. Hypokalemia increases myocardial vulnerability. *Clin Res* 31:2, 635A, 1983.
- A47. Tepper D, Hoch R, Koegler L, Kleinbaum H, Butler B, Felder, T, Torres V, Miura DS, Somberg JC. The lack of effect of bepridil on serum digoxin concentration. *Clin Res* 1983.
- A48. Somberg JC, Kern G, Siegel L, Tepper D, Butler B, Keefe D, Miura DS. The comparative effects of lorcaïnide, procainamide, and lidocaine on suppressing ventricular tachycardia induced by programmed stimulation. *J Am Col Cardiol*, 1(2): 670, 1983.
- A49. Butler B, Somberg JC, Altman C, Kern G, Levitt B, Miura DS. Effect of cimetidine in decreasing myocardial sensitivity to digitalis toxicity. *J Am Col Cardiol*, 1(2) P: 686, 1983.
- A50. Miura DS, Keren G, Siegel L, Tepper D, Butler B, Aogaichi K, Somberg JC. Effect of cibenzoline in suppressing ventricular tachycardia induced by programmed stimulation. *J Am Col Cardiol*, 1(2); 699, 1983.
- A51. Somberg JC, Keren G, Siegel L, Willens H, Jentzer J, Tepper D, Butler B, Keefe D, Sonnenblick E, Miura DS. Programmed electrical stimulation guided therapy for post myocardial infarction arrhythmias. *J Am Col Cardiol*, 1(2): 717, 1983.
- A52. Somberg JC, Torres V, Butler B, Keefe D, Sonnenblick E, Miura DS. Programmed electrical stimulation guided therapy for late post infarction ventricular tachycardia. *Circulation* 68:4, III-285, 1983.
- A53. Somberg JC. Centrally mediate coronary vasoconstriction. *Circulation* 68:4, III-31, 1983.
- A54. Somberg JC, Torres V, Gottlieb S, Butler D, Levitt B, Miura D. The enhancement of myocardial vulnerability by atrial fibrillation. *Circulation* 68:4, III-56, 1983.
- A55. Frishman WH, Rosen S, Cohen M, Strom J, Somberg JC, Croer L, Lief P. Return to Science: An integrated approach for teaching cardiovascular medicine and preventive cardiology to senior students. *Circulation* 68:4, III-285, 1983.
- A56. Torres V, Flowers D, Butler B, Wynn J, Keefe D, Miura D, Somberg JC. The antiarrhythmic action of bethanidine. *J Am Col Cardiol* 3:2, 557, 1984.

- A57. Torres V, Flowers D, Butler B, Miura D, Somberg JC. Antiarrhythmic action of bedridil: A long acting calcium blocker with antiarrhythmic properties. *J Am Col Cardiol* 3:2, 558, 1984.
- A58. Flowers D, Butler B, Torres V, Keefe D, Miura D, Somberg J: Programmed electrical stimulation guided antiarrhythmic therapy: a long-term follow up. *Clin Res* 32:2, 164A, 1984.
- A59. Miura D, Karen G, Tepper D, Butler B, Somberg J, Frishman W. Non-invasive assessment of the efficacy of labetalol the use of autonomic profile. *Clin Res* 32:2, 189A, 1984.
- A60. Torres V, Butler B, Miura D, Gottlieb S, Keefe D, Somberg J. Arrhythmogenicity of antiarrhythmic agents as assessed by programmed electrical stimulation. *Clin Res* 32:2, 189A, 1984.
- A61. Torres V, Felder J, Hoch R, Tepper D, Weiner D, Somberg JC. The antiarrhythmic action of bepridil in normokalemic and hypokalemic dogs. *Fed Proc* 43: 4, 842, 1984.
- A62. Butler B, Tepper D, Miura D, Levitt B, Somberg JC. An animal model demonstrating efficacy of amiodarone. *Fed Proc* 43:4, 843, 1984.
- A63. Flowers D, Butler B, Torres V, Keefe D, Miura D, Somberg JC. Programmed electrical stimulation guided antiarrhythmic therapy: A long term follow-up. *Eur Heart J* 5:1, 263, 1984.
- A64. Torres V, Williams S, O'Gallagher D, Teribile S, Somberg JC, Keefe D. Comparative assessment of Quinidine and Encainide. *Clinical Pharmacol Therap* 37:P2, 233, 1985.
- A65. Flowers D, Torres V, Somberg JC. Ethmozine antiarrhythmic profile in the drug resistant patient with ventricular tachycardia. *International Symposium, Cardiovascular Pharmacotherapy, Geneva, Switzerland, April 1985.*
- A66. Somberg JC, Sarda MA, Tepper D, Capasso J. Cardiac arrhythmogenic Effects of electrical stimulation of the area postrema in the infarcted rat. *Clin Res* 33:2, 230A, 1985.
- A67. Torres V, Tepper D, Flowers D, Wynn J, Kleinbaum H, Miura D, Keefe D, Somberg JC. Prognostic significance of QT prolongation in patients receiving amiodarone. *Clin Res* 33:2, 233A, 1985.
- A68. Torres V, Flowers D, Wynn J, Somberg JC. Does suppression of ventricular ectopic activity correlate with prevention of inducible ventricular tachycardia. *Clin Res* 33:2, 233A, 1985.
- A69. Wynn J, Flowers D, Somberg JC. Predictors of efficacy of class III drugs at electrophysiologic testing. *Clin Res* 33:2, 239A, 1985.
- A70. Wynn J, Flowers D, Torres V, Mizruchi M, Miura D, Somberg, JC. Procainamide as a predictor of efficacy for other agents at programmed electrical stimulation testing. *Clin Res* 33:2, 239A, 1985.

- A71. Flowers D, Torres V, Somberg JC. Ethmozine: Antiarrhythmic profile in the drug resistant patient with ventricular tachycardia. Cardiovascular Pharmacotherapy International Symposium, Geneva, Switzerland, April 22-25, #364, 1985.
- A72. Williams S, Wynn J, Torres V, Keefe D, Miura D, Somberg JC. Antiarrhythmic efficacy of IV amiodarone in patients with incessant VT. Clin Pharm 25:6, 464, 1985.
- A73. Wynn J, Torres V, Miura D, Somberg JC. N-acetylprocainamide: Antiarrhythmic profile in patients with cardiac arrest. J Clin Pharm 25:6, 465, 1985.
- A74. Laux B, Wynn J, Torres V, Miura D, Somberg JC. Efficacy of class Ic agents in patients with cardiac arrest and symptomatic VT. J Clin Pharm 25:6, 465, 1985.
- A75. Keefe D, Williams S, Flowers D, Torres V, Somberg JC. Comparison of tocainide and lidocaine for prophylaxis of ventricular arrhythmias in patients with acute MI. J Clin Pharm 25:6, 465, 1985.
- A76. Torres V, Tepper D, Flowers D, Wynn J, Kleinbaum H, Miura D, Keefe D, Somberg JC. Prognostic significance of QT prolongation in patients receiving amiodarone. J Clin Pharm 25:6, 470, 1985.
- A77. Torres V, Flowers D, Wynn J, Somberg JC. Does prevention of inducible ventricular tachycardia correlate with suppression of ventricular ectopic activity. J Clin Pharm 25:6, 470, 1985.
- A78. Wynn J, Miura D, Torres V, Laux B, Williams S, Somberg JC. Antiarrhythmic properties of ethmozine in patients with vermicular tachycardia as determined by PES. J Clin Pharm 25:6, 470, 1985.
- A79. Keefe D, Williams S, Miura D, Teribile S, Somberg JC. A randomized parallel of cibenzoline and quinidine for prevention of recurrence of atrial fibrillation or flutter. J Clin Pharm 25:6, 470, 1985.
- A80. Sarda MA, Williams S, Somberg JC. Dietary amino acid modification can attenuate coronary occlusion arrhythmias. Circulation 72, 3:226, 1985.
- A81. Tepper D, Reichman P, Somberg JC, Capasso JM, Sonnenblick E. Quabain cardiotoxicity in the rat: A new model for studying arrhythmogenicity. Clin Res 33:2, 232A, 1985.
- A82. Conti R, Bailey K, Keefe D, Somberg JC, Turlapaty P. Comparison of flestolol an ultra-short acting beta blocker with IV nitroglycerin in unstable angina. 10th World Congress of Cardiology, 1986.
- A83. Zanger D, Wynn W, Miura D, Strom J, Keefe D, Schwartz J, Tepper D, Maze S, Somberg J. Cardiac determinants of inducibility in patients presenting for electrophysiologic study with syncope. Clin Res 34:2, 357A, 1986.
- A84. Wynn J, Miura D, Torres V, Keefe D, Berchin B, Flowers D, Somberg JC. Long term

- survival of patients undergoing cardiac electrophysiologic studies. *Clin Res* 34:2, 356A, 1986.
- A85. Fingerhood M, Tepper D, Wynn J, Mira D, Keefe D, Somberg J. Does the ejection fraction effect the time interval from ventricular tachycardia induction to defibrillation at electrophysiologic testing? *Clin Res* 34:2, 298A, 1986.
- A86. Schwartz J, Wynn J, Maza S, Laux B, Keefe D, Miura D, Somberg J. Antiarrhythmic properties of d-sotalol in patients with ventricular tachycardia determined by programmed electrical stimulation. *J Am Col Cardiol* 7:2, 93A, 1986.
- A87. Tepper D, Sarda KA, Capasso TM, Kleinbaum H, Williams S, Somberg JC. Does hypertensive hypertrophy cause myocardial electrical instability. *J Am Col Cardiol* 7:2, 111A, 1986.
- A88. Maze SR, Wynn J, Schwartz J, Zanger D, Keefe D, Miura D, Somberg JC. Treatment of flecainide induces ventricular tachycardia with lidocaine. *J Am Col Cardiol* 7:2, 159A, 1986.
- A89. Somberg JC, Schwartz J, Torres V, Wynn J, Keefe D, Mill D. Does suppression of ventricular ectopic activity correlate with prevention of inducible ventricular tachycardia. *J Am Col Cardiol* 7:2, 159A, 1986.
- A90. Somberg JC, Schwartz J, Miura D, Keefe D. Dose does not predict antiarrhythmic efficacy of d-sotalol at electrophysiologic studies. *J Clin Pharm* 26:7, 542A, 1986.
- A91. Somberg JC, Tepper D, Keefe DL. Incessant VT treated with IV amiodarone: Rapid onset of action with a long half-life agent. *J Clin Pharm* 26:7, 542A, 1986.
- A92. Miura D, Wynn J, Laux B, Keefe D, Somberg JC. Comparative efficacy of indecainide versus procainamide in patients with ventricular tachycardia determined by programmed electrical stimulation. *J Clin Pharm* 26:7, 533A, 1986.
- A93. Somberg JC, Laux B, Schwartz J, Keefe D, Miura D. Does intravenous testing of flecainide predict outcome of oral therapy? *J Clin Pharm* 26:7, 542A, 1986.
- A94. MacCosbe PE, Katz R, Steinberg J, Keefe D, Somberg J, Burge J, Turlapaty P, Laddu A. Flestolol - A short acting beta-blocking agent in acute supraventricular tachyrrhythmia. *Drug Intelligence and Clinical Pharmacy* 20:457, 1986.
- A95. Anderson TL, Askins JC, Gilbert E, Miller R, Keefe D, Somberg JC, Freedman RA, Haft L, Mason J, Lessen J. Controlled multi-center evaluation of sotalol for suppression of complex ventricular arrhythmias. *Circulation* 74:II, 311, 1986.
- A96. Schwartz J, Crocker K, Somberg JC. Refractoriness as a determinant of right ventricular inducibility. *Clin Res* 35:3, 325, 1987.
- A97. Schwartz J, Crocker K, Horowitz K, Lapsker J, Miura D, Somberg J. Comparison of time domain and frequency domain analysis in predicting inducibility at electrophysiology testing. *Clin Res* 35:3, 325, 1987.



- A98. Somberg J, Capasso J, Leon L, Tepper D. Does lidocaine effect flecainide induced ventricular arrhythmias? *Clin Res* 35:3, 328, 1987.
- A99. Schwartz R, Tepper D, Levitt B, Miura, D, Keefe D, Somberg J. The time course of QT prolongation with oral amiodarone therapy. *J Clin Pharm* 27, 9:707, 1987.
- A100. Somberg JC, Schwartz J, Miura D, Keefe D. Long term antiarrhythmic efficacy of oral d-sotalol. *J Clin Pharm* 27, 9:708, 1987.
- A101. Somberg JC, Schwartz J, Wynn J, Keefe D, Miura D. Long term efficacy of flecainide as determined by acute electrophysiologic studies. *J Clin Pharm* 27, 9:708, 1987.
- A102. Landau S, Kaminetzky J, Hogan C, Tepper D, Tullo N, Somberg JC. Comparison of the cardiac electrophysiologic effects of Isradipine and Verapamil in man. *J Clin Pharm* 28, 10:909, 1986.
- A103. Hogan C, Landau S, Tepper D, Somberg JC. Cimetidine Amiodarone Interaction. *J Clin Pharm* 28, 10:909, 1988.
- A104. Landau S, Hogan C, Butler B, Somberg JC. The combined administration of verapamil and flecainide. *J Clin Pharm* 28, 10:909, 1988.
- A105. Landau S, Hogan C, Somberg JC. Evaluation of a Possible Electrophysiologic Interaction of Flecainide and Lidocaine. *J Clin Pharm* 28, 10:910, 1988.
- A106. Weinstein A, Zevitz M, Deshmukh H, Gergans G, Nowak T, Somberg J. Dose-Related Effects of Oral Dipyridamole in Thallium Imaging. *J Clin Pharm* 29, 9:862, 1989.
- A107. Dharamsey S, Ehrenpreis S, Somberg J. The Antiarrhythmic Effects of a New B-Halo Alkyl Derivative of Lidocaine. *ASPET* August, 1990.
- A108. Weinstein A, Zevitz M, Gergans G, Deshmukh H, Nowak T, Singh R, Bushnell D, Somberg J. A Comparison of IV Adenosine vs. Oral Dipyridamole in Thallium Imaging. *J Clin Pharm* 30, 9:858, 1990.
- A109. Weinstein A, Zevitz M, Deshmukh H, Gergans G, Nowak T, Somberg J. Incremental Dosing of Oral Dipyridamole in the Performance of Thallium Imaging. *J Clin Pharm* 30, 9:850, 1990.
- A110. Zevitz M, Varga D, Somberg J. The Effect of Isosorbide Dinitrite on Exercise Performance in Patients on Captopril, Digoxin and Diuretic Therapy. *J Clin Pharm* 30, 9:858, 1990.
- A111. Weinstein A, Bushnell D, Gergans G, Deshmukh H, Balachandra D, Emanuelle T, Somberg J. A Comparison of IV Adenosine Vs Oral Dipyridamole in Thallium Imaging. Presented March 6, 1991, 40th Annual Scientific Session, American College of Cardiology, Atlanta, Georgia.
- A112. Cao W, Ehrenpreis S, Emmanuelle T, Coutinho N, Nowak T, Somberg J. The Discordance Between Ectopy Suppression, Sustained Arrhythmia Control and Pharmacodynamic Action of Type III Agents. *J Clin Pharm*, 31, 9:942, 1991.

- A113. Lavie E, Emmanuelle T, Coutinho N, Nowak I, Gergans G, Somberg J. A Comparison of Tablet to Oral Suspension Formulation of Dipyridamole in Thallium Myocardial Imaging. *J Clin Pharm*, 31, 9:843, 1991.
- A114. Somberg JC, Cao W, Ehrenpreis S. The Effects of Age on Coronary Occlusion Arrhythmias. *J Clin Pharm*, 32, 8:746, 1992.
- A115. Coutinho N, Khosla S, Colucci R, Somberg JC. Can Nitroglycerine Turn Angina Into Silent Ischemia? *J Clin Pharm*, 32, 8:747, 1992.
- A116. Jaffrani N, Cao W, Ehrenpreis S, Ranade V, Somberg J. Intravenous Nitroglycerin Causing Heparin Resistance. *J Clin Pharm*, 33:1001, 1993.
- A117. Somberg J, Cao W, Ranade V, Jaffrani N, Ehrenpreis S. The Nitroprusside/Heparin Interaction. *J Clin Pharm*, 33:1001, 1993.
- A118. Cao W, Colucci R, Ehrenpreis S, Somberg J. The Effect of Magnesium Sulfate on Action Potential Duration and Cardiac Arrhythmias. *J Clin Pharm*, 33:1001, 1993.
- A119. Cao W, Jaffrani N, Ehrenpreis S, Ranade V, Sacher H, Somberg J. Does Low Molecular weight Heparin Interact With Nitroglycerine? *J Clin Pharm*, 33:1001, 1993.
- A120. Somberg J, Cao W, Ranade V. A New Aqueous Preparation of Amiodarone. *Circulation Oct Suppl.* 92(8): I-195 (0933), 1995.
- A121. Yelamanchi Y, Ranade V, Cao W, Khosla S, Duggal C, Jaffrani N, Somberg JC. Influence of Electrolyte Abnormality on Interlead Variability of Ventricular Repolarization Times in 12-lead ECG. *J of Inv Med* 43(3): 430A, 1995.
- A122. Jaffrani N, Cao W, Ranade V, and Somberg JC. The Mechanisms of the Heparin-Nitroglycerin Interaction. *J of Inv Med* 43(3): 478A, 1995.
- A123. Cao W, Ranade V, Khosla S, Duggal C, and Somberg JC. The Effect of Epinephrine and Coronary Occlusion on QT Dispersion. *J of Inv Med* 43(3): 453A, 1995.
- A124. Cao W, Ranade V, Jaffrani N, and Somberg JC. Is There a Nitroglycerin Hirulog Interaction? *J of Inv Med* 43(3): 427A, 1995.
- A125. Cao W, Ranade V, Khosla S, and Somberg JC. Beta Blockade and Amiodarone: Is There a Problem? *J of Inv Med* 43(3): 430A, 1995.
- A126. Somberg JC, Cao W, Ranade V. New Aqueous Preparation of Amiodarone. *J of Inv Med* 43(3): 430A, 1995.
- A127. Cao W, Ranade V, Jaffrani N, Khosla S, and Somberg JC. Relationship between QT Dispersion and Action Potential Duration. *J of Inv Med* 43(3): 430A, 1995.

- A128. Cao W, Ranade V, Jaffrani N, and Somberg JC. The Effect of Quinidine, Amiodarone, and Sotalol on QT Dispersion. *J of Inv Med* 43(3): 430A, 1995.
- A129. Jaffrani N, Cao W, Ranade V, Somberg J. Intravenous Nitroglycerin Causing Heparin Resistance. *Proceedings of the American College of Cardiology, JACC* 27(2): 326A, 1996.
- A130. Molnar J, Jerry W, Rosenthal JE, Somberg JC. Circadian Variation of QT Dispersion in Survivors of Sudden Cardiac Death. *PACE* 19(II) 688A, 1996.
- A131. Molnar J, Ichkhan K, Rosenthal J, Somberg J. Validation of a new computer-assisted method for QT Dispersion Measurement from Holter Recordings. *J Inv Med* 44 (7): 350A, 1996.
- A132. Tarabey R, Sukenik D, Syed M, Molnar J, Somberg J. The Effect of Acute Coronary Occlusion at Angioplasty on QT Dispersion. *J Inv Med* 44(7): 374A, 1996.
- A133. Cao W, Ranade V, Somberg J. The Effect of Epinephrine and Coronary Occlusion on QT Dispersion. *J Inv Med* 44 (7): 349A, 1996
- A134. Somberg JC, Cao W, Ranade V, Jaffrani N, Molnar J. The Effect of Quinidine, Amiodarone, Sotalol and Coronary Occlusion on QT Dispersion. *J Inv Med* 44(7): 343A, 1996.
- A135. Ranade V, Cao W, Agarwal A, Somberg J. Validation of the Method for Determination of ACE Levels in Normal Volunteers. *J Inv Med* 44(7): 352A, 1996.
- A136. Cao W, Yelamanchi V, Ranade V, Colluchi R, Somberg J. Effects of Diet Induced Hypokalemia and Hypomagnesemia on QT and QTC Interval Dispersion in Rats. *J Inv Med* 44(7): 349A, 1996
- A137. Somberg J, Khosla S, Duggal C, Siddiqi R, Vohra V, O'Connor T. The Effect of Mechanical Revascularization on Dispersion of Ventricular Repolarization. *J Inv Med* 44(7): 374A, 1996.
- A138. Zukowski T, Molnar J, Somberg J. Left Bundle Branch Block and QT Dispersion, An EKG Evaluation. *J Inv Med* 44 (7): 350A, 1996.
- A139. Ichkhan K, Molnar J, Somberg J. The Correlation of Left Ventricular Mass and QT Dispersion in Hypertensive Patients. *J Inv Med* 44(7): 350A, 1996.
- A140. Nomani R, Somberg J. B2 Agonist Inhalation and QTc Dispersion. *J Inv Med* 44(7): 343A, 1996.
- A141. Somberg JC, Molnar T, Weiss JS, Rosenthal 72. QT interval dispersion in survivors of sudden cardiac death: a 24-hour assessment. *European Heart J* 17(Supp): 29:248, 1996.
- A142. Yelamanchi V, Ranade V, Cao W, Khosla S, Duggal C, Jaffrani N, Somberg J. Influence of Electrolyte, Abnormality on Interlead Variability of Ventricular Repolarization Times in 12-Lead ECO. *J Am Col Cardio* 29(2): 148A, 1997.

- A143. Ichkhan K, Molnar T, Somberg J. The Correlation of Left Ventricular Mass and QT Dispersion in Hypertensive Patients. *J Am Col Cardio* 29(2): 162A, 1997.
- A144. Molnar J, Rosenthal J, Somberg J. Gender Differences in the Circadian Patter of CT Intervals and QT Dispersion: A 24 -Hour Holter Assessment. *PACE* 20(4): 597A, 1997.
- A145. Molnar J, Weiss J, Rosenthal J, Somberg J. Circadian Variation of QT Dispersion in Survivors of Cardiac Arrest. *PACE* 20(4): 511A, 1997.
- A146. Molnar J, Weiss JS, Rosenthal JE, Somberg JC. Dynamic QT Dispersion: A Marker for Sudden Cardiac Death. *J Inv Med* 45(3): 222A, 1997.
- A147. Molnar T, Rosenthal J, Somberg J. Gender Differences in the Circadian Patter of QT Intervals and QT Dispersion: A 24 Hour Holter Assessment. Submitted to the European Society of Cardiology, 1997, Stockholm, Sweden. *Int J Cardio* 1997.
- A148. Khokher I, Najeed S, Agarwal A, Molnar J, Ranade V, Somberg JC. ACE Inhibitor Therapy Decreases QT Dispersion in Patients with Chronic Heart Failure. *American Heart Association* 5/97.
- A149. Najeed S, Khokher T, Molnar J, Gazmuri R, Somberg JC. The Differential Effect of Glyburide and Metformin on QT Dispersion: A potential K<sup>+</sup> Sensitive ATP Channel Effect. *American Heart Association* 5/97.
- A150. Molnar J, Rosenthal JE, Somberg JC. Gender Differences in QT Intervals and QT Dispersion: A 24 Hour Holter Assessment. *American Federation for Medical Research, Midwestern Section*, 6/97.
- A151. Najeed SA, Molnar J, Gazmuri R, Somberg JC. The Differential Effect of Glyburide and Metformin on QT Dispersion: A Potential K<sup>+</sup> Sensitive ATP Channel Effect. *American Federation for Medical Research, Midwestern Section*, 6/97.
- A152. Siddiqi R, Shroff G, Hanif S, Molnar J, Vohra V, O'Connor T, Somberg JC. Effects of Intravenous Thrombolysis in Acute Myocardial Infarction on QT Dispersion. *American Federation for Medical Research, Midwestern Section*, 6/97.
- A153. Hanif S, Molnar J, Somberg TC. Comparison of the Effect of Class IA and Type III Antiarrhythmic Agents on QT Dispersion. *American Federation for Medical Research, Midwestern Section*, 6/97.
- A154. Somberg J, Oberti C, Pinna B, Ranade V. The Effect of Quinidine and Quinine on a Potassium Current (I<sub>Kr</sub>). *J Mol Cell Cardio* 33:6, AII3, 2001.
- A155. Somberg J, Cvetanovic I, Cao W, Ranade V. Does IV Metolazone Potentiate the Diuretic Action of IV Furosemide? *J Mol Cell Cardio* 33:6 A1 13, 2001.
- A156. Khokher T, Najeed S, Agarwal A, Molnar J, Ranade V, Somberg J. ACE Inhibitor therapy decreases QT dispersion in patients with chronic heart failure. *Circulation* 96:1664, 1997.

- A157. Wolf ME, Ranade VV, Somberg J, Lutz G, Mosnaim AD. Bipolar disorder, arrhythmia and anticonvulsants. *Biol Psychiatry* 43:IS-1335, 1998.
- A158. Wolf ME, Ranade VV, Somberg J, Lutz G, Mosnaim AD. Hypercalcemia, arrhythmia and psychotic drugs. *Biol Psychiatry* 45:1365, 1999.
- A159. Somberg JC, Cvetanovic I, Cao W, Ranade VV. Does EV metolazone potentiate the diuretic action of IV furosemide? *J Mole Cell Cardiol* 33:6, A113.
- A160. Somberg JC, Oberti C, Pinna B, Ranade VV. The effect of quinidine and quinine on a potassium current (I<sub>Kr</sub>). *J Mole Cell Cardiol* 33:6,A113.
- A161. Cvetanovic I, Cao W, Ranade VV, Somberg JC. Metolazone IV potentiates the diuretic action of furosemide AFCR meeting. *J Inv Med* 2001.
- A162. Somberg J, Cvetanovic I, Oberti C, Congrong L, Ranade VV. The differential effects of chiral isolates of quinidine. *J Inv Med* 2001.
- A163. Ranade V, Molnar J, Somberg J. QT Measurements following ACE therapy. *J Inv Med* 50:5, Sept. 2002.
- A164. Somberg J, Balin S, Haffajee C, et al The treatment of incessant ventricular tachycardia: lidocaine versus a new aqueous formulation of amiodarone. *Circulation* 106:19, November 5, 2002.
- A165. Somberg J, Agarwal A, Molnar J, Ranade V. QT Measurements following ACE therapy. *Clinical Pharmacology & Therapeutics*. 73:2, February 2003.

## **PUBLICATIONS**

1. Somberg JC, Happ G, Schneider A. Retention of a conditioned avoidance response after metamorphosis in mealworms. *Nature* 288:87, 1970.
2. Somberg JC, Happ G, Schneider A. Retention of a conditioned avoidance response. *Mental Health Digest* 3:3, 1971.
3. Levitt B, Cagin N, Somberg J, Bounous H, Mittag T, Raines A. Alteration of the effects of distribution of ouabain by spinal cord transection in the cat. *J Pharmacol Exp Therp* 185:24-28, 1973.
4. Diaz R, Somberg J, Freeman E, Levitt B. Withdrawal of Propranolol and myocardial infarction. *Lancet* 1:1068, 1973.
5. Cagin N, Freeman E, Somberg JC, Bounous H, Mittag T, Diaz R, Levitt B. The influence of propranolol on ouabain uptake by the guinea pig heart. *Eur J Pharmacol* 23:3,256-61, 1973.
6. Cagin N, Freeman E, Somberg J, Mittag T, Raines A, Levitt S. A comparison of the in vivo and in vitro actions of ouabain to produce cardiac arrhythmia. *Arch Int de Pharmacodyn, et de Theran* 207:162-169, 1974.

7. Cagin N, Somberg JC, Bounous H, Mittag T, Raines A, Levitt B. The influence of spinal cord transaction on the capacity of digoxin to induce cardiotoxicity. *Arch Int de Therap* 207:304-347, 1974.
8. Diaz R, Somberg J, Freeman E, Levitt B. Myocardial infarction after Propranolol withdrawal. *Am Heart J* 88:257-258, 1974.
9. Rosenthal W, Cagin N, Somberg T, Pitchumoni C, Levitt B. The influence of metiamide on ouabain cardiotoxicity. *Eur J Pharmacol* 34:233-236, 1975.
10. Cagin N, Somberg J, Kleid J, Gillis R, Levitt B. Drugs for arrhythmias. *Lancet* 2:277-278, 1975.
11. Somberg J, Cagin N, Kleid J, Gillis R, Levitt B. The influence of metiamide on ouabain cardiotoxicity. *Eur J Pharmacol* 34:233-236, 1975.
12. Levitt B, Cagin N, Kleid J, Somberg J, Gillis R. The role of the nervous system in the genesis of cardiac rhythm disorders. *Am J Cardiol* 37:7, 1111-1113, 1976.
13. Somberg J, Cagin N, Gillis R, Levitt B. The action of Propranolol in man and animals. *Circulation* 53:205-206, 1976.
14. Cagin N, Somberg J, Kleid J, Levitt B. Ventricular premature beats and sudden cardiac death. *Prac Cardiol* 20-31, Oct, 1976.
15. Levitt B, Cagin N, Somberg J, Kleid T. Ventricular rhythm disorders and sudden cardiac death. *Am J Med* 61:4,449-451, 1976.
16. Levitt B, Cagin N, Somberg J, Kleid J. Neural basis for the genesis and control of digitalis arrhythmias. *Cardio* 61:5060, 1976.
17. Cagin N, Somberg J, Bounous H, Mittag T, Raines A, Levitt B. Ouabain cardiotoxicity a reassessment of methodology. *Arch Int Pharmacodyn* 222:250-258, 1976.
18. Cagin N, Somberg J, Kleid J, Levitt B. Digitalis: New knowledge about an old drug. *Cardiovasc Med* 2:183-192, 1977.
19. Somberg J, Cagin N, Bounous H, Levitt B. Adriamycin cardiotoxicity. *Br J Cancer* 35:123,1977.
20. Somberg J, Cagin N, Levitt B, Kleid J, Levi R, Gerrity M, Bounous H. The influence of histamine H2 receptor antagonists on ouabain cardiotoxicity in the cat. *Am J Cardiol* 39:275, 1971.
21. Cagin N, Somberg J, Bounous H, Levitt B. A comparison of Actodigin and ouabain in the cat. *Arch Int Pharmacodyn* 226:263-269, 1977.
22. Levitt B, Cagin N, Kleid J, Somberg J. Anti-anginal therapy: A physiological approach. *Hospital Formulary* 12:659-662, 1977.

23. Somberg J, Bounous G, Cagin N, Anagnostopoulos C, Levitt B. The influence of prostaglandin E1 and E2 on ouabain cardiotoxicity in the cat. *J Pharm Exp Ther* 203:480-484, 1977.
24. Cagin N, Benda R, Somberg J, Levitt B. Refractory heart failure. *New York State Journal of Medicine* 888-890, 1978.
25. Somberg J, Cagin N, Levitt B, Bounous H, Ready P, Leonard D, Anagnostopoulos C. Blockade of tissue uptake of the antineoplastic agent, doxorubicin. *J Pharm Exp Ther* 204:226-29, 1978.
26. Cagin N, Somberg J, Freedman H, Bounous H, Raines A, Levitt B. The influence of heart rate on ouabain cardiotoxicity in cats with spinal cord transection. *Europ J Pharmacol* 50:6974, 1978.
27. Bounous H, Cagin N, Levitt B, Somberg J. The effect of diphenidol on ouabain cardiotoxicity in the cat. *Br J Pharmacol* 63:73-77, 1978.
28. Somberg J, Risler T, Smith TW. Neural factors in digitalis toxicity: protective effect of C-1 spinal cord transection. *Am J Physiol* 235 (5) -H531-H536, 1978.
29. Somberg JC, Bounous H, Levitt B. The capacity of quinidine and propranolol to antagonize ouabain-induced arrhythmias in the neurally deprived cat. *Europ J Pharmacol* 54:161-166, 1979.
30. Somberg J, Smith T. Localization of the neurally mediated arrhythmogenic properties of digitalis. *Science* 204:321-323, 1979.
31. Risler T, Somberg J, Blute R, Smith TW. The effect of altered renal perfusion pressure on the clearance of digoxin. *Circulation* 61:521-525, 1980.
32. Somberg J, Mudge GH, Risler T, Smith TW. Neurally mediated augmentation of the arrhythmogenic properties of highly polar cardiac glycosides. *Am J Physiol* 238:H202-H208, 1980.
33. Somberg JC, Bounous H, Levitt B. Histamine antagonists as antiarrhythmic agents in ouabain cardiotoxicity in the cat. *J Pharmacol Exp Ther* 214:P375-380, 1980.
34. Somberg JC, Barry WH, Smith TW. Differing sensitivities of Purkinje fibers and myocardium to inhibition of monovalent cation transport by Digitalis. *J Clin Invest* 67:116-123, 1981.
35. Somberg JC, Kuhlman JE, Smith TW. Localization of the neurally mediated coronary vasoconstrictor properties of digitalis in the cat. *Circ Res* 49:226-233, 1981.
36. Miura DS, Somberg JC. The clinical management of cardiac rhythm disorders. *Cardiovasc Rev* 2:4,402-412, 1981.

37. Risler T, Somberg JC, Smith TW. Renal elimination of digoxin: Studies with titrated digoxin and radioimmunoassay. *J Pharmacol Exp Ther* 218:368-374, 1981.
38. Somberg JC, Miura DS, Keren G, Frishman W, Sonnenblick E. Pharmacology of nitrates and other drugs in the treatment of ischemic heart disease. *Cardiovasc Rev & Re* 3:10,1450-1458, 1982.
39. Somberg JC, Sonnenblick EH, Miura DS. Antiarrhythmic drug selection using programmed electrical stimulation. *Terapeuticheskii Arkhiv* II:97-98, 1982.
40. Frishman W, Somberg JC. Comparative effects of calcium entry blockers and long-acting nitrates in the therapy for angina pectoris. *Cardiovasc Rev & Rep* 3:10, 1435-1443, 1982 .
41. Somberg JC, Karen G, Miura DS, Frishman W. Pharmacology of drugs in the treatment of ischemic heart disease. *Resident Staff and Physician* 28:32-48, 1982.
42. Somberg JC, Knox S, Miura DS. The affect of quinidine on the differing sensitivities of Purkinje fibers and myocardium to inhibition of monovalent cation transport by digitalis. *Am J Cardiol* 52:123-126, 1983.
43. Knapp AB, Maguire W, Karen G, Karmen A, Levitt B, Miura DS, Somberg JC. The Cimetidine-Lidocaine Interaction. *Annals of Internal Medicine* 98:2,174-177, 1983.
44. Karen G, Miura D, Somberg J. Pacing termination of ventricular tachycardia. *Am Heart T* 107:4, 638-643, 1983.
45. Raghavan N, Miura DS, Somberg JC. Amiodarone: An experimental, but clinically useful antiarrhythmic agent. *Cardiovasc Rev & Rep* 4:5,701-708, 1983.
46. Goldberg D, Miura DS, Somberg JC. Flecainide - A promising investigational antiarrhythmic agent. *Cardiovasc Rev & Rep* 4:8,1058-1061, 1983.
47. Spivack C, Gottlieb S, Miura DS, Somberg JC. Flecainide Toxicity. *Am T Cardiol* 53:2,329-330, 1983.
48. Wynn J, Torres V, Tepper D, Somberg JC. New Therapy Focus: Bethanidine. *Cardiovasc Rev & Rep* 52,199-202, 1984.
49. Somberg J. New direction in antiarrhythmic drug therapy. *Am J Cardiol* 54:4,8-17, 1984.
50. Brazzell R, Aogaichi K, Jenson J, Somberg J, Carliner N, Morganroth J. Cibenzoline plasma concentration and antiarrhythmic effect. *Clin Pharm Ther* 35:3,307-316, 1984.
51. Kovacs J, Tuzel I, Aogaichi X, Heger J, Richmond L, Somberg J, Butler B. False-positive urine protein reaction with cibenzoline, a new antiarrhythmic agent. *J Clin Pharm* 24:127-128, 1984.
52. Tepper D, Somberg J. Mexiletine: An investigational antiarrhythmic agent.



- Cardiovasc Rev & Rep 5:1,1138-1141, 1984.
53. Karen G, Tepper D, Butler B, Miura D, Aogaichi K, Somberg J. The efficacy of cibenzoline in preventing PES induction of ventricular tachycardia in the dog. *J Clin Pharm* 24:4464-72, 1984.
  54. Somberg JC, Butler B, Torres V, Flowers D, Tepper D, Wynn T, Karen G, Miura D. Antiarrhythmic action of bethanidine. *Am J Cardiol* 54:4,8-18, 1984.
  55. Somberg JC. Localization of neurally mediated arrhythmogenic vasoconstrictor properties of digitalis. *Fed Proc* 43:2963-2965, 1984.
  56. Somberg J, Butler B, Flowers D, Tepper D, Maguire W, Willens H, Karen G, Miura D. Comparison of non-invasive arrhythmia provocation techniques to electrophysiologic studies and the evaluation of lorcinide in patients with symptomatic ventricular tachycardia. *Am J Cardiol* 54:4, 1984.
  57. Somberg J, Butler B, Torres V, Flowers D, Tepper D, Keefe D, Miura D. Lorcinide therapy for the high risk patient post MI. *Am J Cardiol* 54:37-43, 1984.
  58. Somberg J, Butler B, Flowers D, Keefe D, Torres V, Miura D. The evaluation of lorcinide in patients with symptomatic ventricular tachycardia. *Am J Cardiol* 54:4, 43-49, 1984.
  59. Somberg J. New approach to drug selection and oral drug testing. *J Clin Pharm* 24:320-327, 1984.
  60. Karen G, Tepper D, Butler B, Maguire W, Willens H, Miura D, Somberg JC. Studies on the possible mechanisms of lidoflazine arrhythmogenicity. *J Am Coll Cardiol* 4:742-747, 1984.
  61. Karen G, Tepper D, Butler B, Torres V, Somberg JC. The effect of bepridil, verapamil and quinidine in the prevention of ventricular tachycardia induced by programmed electrical stimulation in the digitalized dog. *Am Heart J* 108:5,1236-1243, 1984.
  62. Keefe D, Somberg JC. New Therapy Focus: Tocainide. *Cardiovasc Rev & Rep* 5:10,1014-1030, 1984.
  63. Ruggio J, Somberg JC. New Therapy Focus: Ethmozine. *Cardiovasc Rev & Rep* 5:7,738-741, 1984.
  64. Torres V, Flowers D, Miura D, Somberg JC. Intravenous quinidine by intermittent bolus for electrophysiologic studies in patients with ventricular tachycardia. *Am Heart J* 108:1437-1442, 1984.
  65. Torres V, Flowers D, Somberg J. The clinical significance of polymorphic ventricular tachycardia provoked at electrophysiologic testing. *Am Heart J* 110:17-24, 1985.
  66. Somberg JC, Miura DS, Levitt B. Digitalis: An update on cardiac glycosides. *Hospital Formulary* 20:11-217, 1985.
  67. Flowers D, O'Gallagher D, Torres V, Miura D, Somberg JC. Flecainide: Long-Term

- Treatment Using a Reduced Dosing Schedule. *Am J Cardiol* 55:79-83, 1985.
68. Somberg J, Butler B, Flowers D, Keefe D, Torres V, Miura D. Long term lorcaïnide therapy in patients with ventricular tachycardia. *Am Heart J* 109:33-40, 1985.
  69. Torres V, Flowers D, Somberg J. The arrhythmogenicity of antiarrhythmic agents. *Am Heart J* 109:5,1090-1097, 1985.
  70. Somberg JC, Tepper D, Wynn J. Prolonged repolarization: An historical perspective. *Am Heart J* 109:2,395-398, 1985.
  71. Somberg JC. Calcium channel blockers that prolong the QT interval. *Am Heart J* 109:2,416-421, 1985.
  72. Somberg J, Torres V, Flowers D, Butler B, Gottlieb S. Prolongation of QT interval and antiarrhythmic action of QT interval and antiarrhythmic action of bepridil. *Am Heart J* 109:19-27, 1985.
  73. Somberg JC, Tepper D. The effect of anti-platelet drugs on electrical stability and instability. *Cardiovasc Rev & Rep* 6:1,30-43, 1985.
  74. Miura D, Karen G, Torres V, Butler B, Aogaichi K, Somberg J. Antiarrhythmic effects of cibenzoline. *Am Heart J* 109:827833, 1985.
  75. Wynn J, Kleinbaum H, Tepper D, Keefe D, Miura D, Torres V, Somberg JC. New Therapy Focus: NAPA. *Cardiovasc Rev & Rep* 6:2,224-248, 1985.
  76. Brazzell R, Colburn W, Aogaichi K, Szuna A, Somberg JC, Carliner N, Heger J, Morganroth J, Winkle R, Block P. Pharmacokinetics of oral cibenzoline in arrhythmia patients. *Clinical Pharmacokinetics* 10:178-186, 1985.
  77. Somberg JC, Butler BA, Torres V, Tepper D, Karen G, Siegel L, Jentzer J, Miura DS. Therapy for late post infarction ventricular tachycardia. *Angiology* 36(3):181-190, 1985.
  78. Somberg JC, Torres V. Approaches to drug selection and serial drug testing. IN: Joel Morganroth and E. Neil Moore, editors. *Cardiac Arrhythmias; New Therapeutic Drugs and Devices*. Boston: Martinus Nijhoff Publishing, 315-334, 1985.
  79. Somberg J, Greenfield B, Tepper D. Digitalis: Historical development in clinical medicine. *J Clin Pharm* 25:484-489, 1985.
  80. Somberg JC. Digitalis: Neurally mediated arrhythmogenic and coronary vasoconstrictor properties. *J Clin Pharm* 25:529-539, 1985.
  81. Somberg JC, Keefe D, Levitt B. Digitalis: Its place in therapy. *J Clin Pharm* 25:555-559, 1985.
  82. Somberg JC, Sonnenblick E. Perspective: The bioequivalence of generic drugs. *Cardiovasc Rev & Rep* 6:9,1010-1015, 1985.

83. Somberg JC, Miura D, Keefe D. The treatment of ventricular rhythm disturbances. *Mod Concept Cardiovasc Dis*, 1985.
84. Miura D, Wynn J, Torres V, Laux B, Flowers D, Keefe D, Somberg JC. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. *Am Heart J* 111:661-666, 1985.
85. Pomrenze H, Tepper D, Somberg JC. Rehabilitation after myocardial infarction: A team approach. *Hospital Medicine* 76-95, August 1985.
86. Miura DS, Dangman KH, Berchin B, Somberg JC. New antiarrhythmic agents: Part 7, the pharmacology and clinical use of cibenzoline. *Practical Cardiology* 11:10,103-117, 1985.
87. Miura DS, Dangman K, Keefe D, Wynn J, Somberg JC. The association of cardiomyopathies and ventricular tachycardia with sudden death. *Cardiovasc Rev & Rep* 6:10,1127-134, 1985.
88. Somberg JC. Digitalis: Its uses and limitations. *Cardio* 2:9,19-20, 1985.
89. Wynn J, Miura D, Torres V, Flowers D, Keefe D, Williams S, Somberg JC. Electrophysiologic evaluation of the antiarrhythmic effects of n-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. *Am J Cardiol* 56:877-881, 1985.
90. Somberg JC, Butler B, Flowers D, Tepper D, Torres V. Long term lorcaïnide therapy guided by electrophysiology studies. *Acta Cardiologica* 6:621-636, 1985.
91. Somberg J. Antiarrhythmic Drug Therapy: Recent advances and current status. *Cardiology* 72:329-348, 1985.
92. Steinberg J, Katz R, Somberg J, Keefe D, Burge J. Flecainide -A new ultra-short acting beta adrenergic blocking agent: Safety and efficacy in supraventricular tachyarrhythmias. *Am J Cardiol* 58:1005-1008, 1986.
93. Anderson J, Askins J, Golbert E, Miller R, Keefe D, Somberg JC, Freedman R, Mason J, Lessem J. Multi-center trial of sotalol for suppression of frequent, complex ventricular arrhythmias. *J Am Coll Cardiol* 8:752-762 1986.
94. Morganroth J, Somberg J, Poole P, Itsu P, Lee I, Durkee J. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. *J Am Cardiol* 7:9-16, 1986.
95. Torres V, Flowers D, Wynn J, Tepper D, Somberg JC. QT prolongation and the antiarrhythmic efficacy of amiodarone. *J Am Coll Cardiol* 7:142-147, 1986.
96. Wynn J, Fingerhood M, Keefe D, Maza S, Miura D, Somberg JC. Refractory ventricular tachycardia with flecainide. *Am Heart J* 112:1,174-175, 1986.

96. Keefe D, Miura D, Somberg JC. Supraventricular tachyarrhythmias: Their evaluation and therapy. *Am Heart J* 111:6,1150-1161, 1986.
97. Somberg JC, Miura D, Keefe D. The treatment of ventricular rhythm disturbances. *Am Heart J* 111:6,1162-1176, 1986.
98. Wynn J, Torres V, Flowers D, Mizruchi M, Keefe D, Miura D, Somberg JC. Antiarrhythmic drug efficacy at electrophysiology testing: Predictive efficacy of procainamide and flecainide. *Am Heart J* 111:632-638, 1986.
100. Somberg JC, Laux B, Wynn J, Keefe D, Miura D. Lorcaïnide in a cardiac arrest population. *Am Heart J* 111:648-653, 1986.
101. Somberg JC, Tepper D. Flecainide: A new antiarrhythmic agent. *Am Heart J* 112:4,808-813, 1986.
102. Miura DS, Wynn J, Laitman R, Laux B, Somberg JC. Ethmozine Toxicity: Fever of unknown origin. *J Clin Pharmacol* 26:153-155, 1986.
103. Flecainide ventricular study group: Treatment of resistant ventricular tachycardia with flecainide acetate. *Am J Cardiol* 57:1299-1304, 1986.
104. Keefe D, Williams S, Torres V, Flowers D, Somberg JC. Prophylactic tocainide or lidocaine in acute myocardial infarction. *Am J Cardiol* 57:527-531, 1986.
105. Keefe D, Somberg JC. Esmolol: A novel ultra-short acting beta blocking agent. *J Clin Pharm* 26: Supp A1-2, 1986.
106. Somberg JC. Antiarrhythmic therapy and the prevention of sudden cardiac death. *Cardiology* 3:3,102-124, 1986.
107. Somberg JC. Antiarrhythmic Drugs: Making sense of the deluge. *Am Heart J* 113:2, 408-412, 1987.
108. Schwartz J, Crocker K, Wynn J, Somberg JC. The antiarrhythmic effects of d-sotalol. *Am Heart J* 114:539-544, 1987.
109. Somberg JC. Intravenous Amiodarone. *Clin Prog Pacing and Electrophysiology* 4:5, 436-441, 1986.
110. Somberg JC. The selection of patients with documented sustained ventricular tachycardia for amiodarone therapy. *Clin Prog Pacing & Electrophysiology* 4:5, 436-441, 1986.
111. Somberg JC, Tepper D, Sacker H, Schwartz J. Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide. *Am Heart J* 114:18, 1987.
112. Tepper D, Keefe D, Miura D, Somberg J. New therapy focus: Lorcaïnide. *Cardiovasc Rev + Rep* 7:11,962-965, 1986.

113. Somberg JC, Schwartz J. Refractoriness as a determinant of tachycardia inducibility in the right ventricle. *Am Heart J* 114:311-314, 1987.
114. Keefe D, Schwartz J, Somberg JC. The substrate and the trigger: The role of myocardial vulnerability in sudden cardiac death. *Am Heart J* 113:1,218-225, 1987.
115. Miura D, Wynn J, Keefe D, Laux B, Somberg JC. Antiarrhythmic effects of indecainide in a drug resistant population with ventricular tachycardia at programmed electrical stimulation. *Am Heart J* 113:65-69, 1987.
116. Somberg J, Wynn J, Miura D, Torres V, Williams S, Keefe-D. N-acetylprocainamide-a antiarrhythmic action in patients with ventricular tachycardia. *Angiology* 37(2) :972-981, 1987 .
117. Somberg JC, Zanger D, Levine E, Tepper D. Encainide: An new and potent antiarrhythmic. *Am Heart J* 114:4,826-835, 1987.
118. Wyndham C, Pratt C, Mean D, Winkle R, Somberg J, DeMaria A, Josephson M. Electrophysiology of ethmozine (moricizine HCL) for ventricular tachycardia. *Am J Cardiol* 60:73-78F, 1987.
119. Somberg JC, Tepper D, Landau S. Propafenone: A new antiarrhythmic agent. *Am Heart J* 115:6,1274-1279, 1988.
120. Kraemer J, Zevitz M, Somberg JC. The Role of Electrophysiologic Testing in the Selection of Amiodarone Therapy. *J Clin Pharm*, 29:429-435, 1989.
121. Zevitz M, Goldman I, Somberg T. Advances in Cardiovascular Antiarrhythmic Therapy. *Annals of Emergency Medicine*, 1990.
122. Demarco, John P, Adenosine for PSVT Study Group. Proximal supraventricular Tachycardia: Dose Ranging in Comparison with Verapamil. Assessment in Placebo Controlled MultiCenter Trial. *Annals of Int Med* 113:104-110, 1990.
123. Somberg J, Kraemer J, Camba N. Amiodarone Therapy Guided by Electrophysiologic Testing: An Update. *Journal of Clinical Pharmacology*, 31:11,1089-1095, 1991.
124. Freedman M, Somberg J. Amiodarone Pharmacokinetic Drug Therapy. *Journal of Clinical Pharmacology*, 31:11, 1061/1069, 1991.
125. Kerin N, Somberg J. Guiding Antiarrhythmic Drug Therapy: Invasive and Non-Invasive Approaches and Experimental models Validating the Arrhythmic Therapy. *Progress in Cardiovascular Diseases*, 1991.
126. Somberg JC, Achari R, Laddu A. Terazosin: Pharmacokinetics and the Effect of Age and Dose on the Incidence of Adverse Side Effects. *Am Heart J* 122:901-905, 1991.
127. Lavie E, Gergans G, Somberg JC. A Comparison of Tablets with Suspension Formulation of Dipyridamole in Thallium Myocardial Imaging. *J Clin Pharm* 32(6):546-552, 1992.

128. Ellyin FM, Kumar Y, Somberg JC. Hypothyroidism Complicated by Angina Pectoris: Therapeutic Approaches. *J Clin Pharm* 32(9):843-847, 1992.
129. Tullo NG, Landau S, Coutinho N, Somberg JC. A Randomized, Comparative Study of the Electrophysiologic and Electrocardiographic Effects of Isradipine versus Verapamil. *ACTA Anesthesiologia Scandinavica, Acta Anaesthesiol Scand* 37(99):43-47, 1993.
130. Martyn R, Kerin NZ, Somberg JC. Pro-arrhythmia of Non-Antiarrhythmic Drugs. *Am Heart J* 126:201-205, 1993.
131. Khosla S, Somberg J. Rationale for the Use of ACE inhibitors in the Treatment of Mild Congestive Heart Failure. *Geriatrics* 48(11)47-54, 1993.
132. Jaffrani NA, Ehrenpreis S, Laddu A, Somberg JC. Therapeutic Approach to Unstable Angina: Nitroglycerin, Heparin and Combined Therapy. *Am Heart J* 126(5) :1239-1242, 1993.
133. Somberg JC. Alpha, Blockade: working in Combination Therapy, Perspectives in Cardiology. *Supplement*:25-31, May, 1993.
134. Somberg J. New FDA initiatives (editorial) *J Clin Pharmacol* 33(7):587, 1993.
135. Somberg JC. Branded generics (editorial) *J Clin Pharmacol* 33(9):779, 1993.
136. Somberg JC. Big Science, Little Science; Science in Controversy (editorial). *J Clin Pharmacol* 33(8):675, 1993.
137. Somberg J, Shroff G, Khosla S, Ehrenpreis S. The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the 1990's. *J Clin Pharmacol* 33 (7):670-673, 1993.
138. Khosla S, Laddu A, Ehrenpreis S, Somberg JC. Cardiovascular effects of Nicotine: Relation to Deleterious Effects of Cigarette Smoking. *Am Heart J* 127:1669-1672, 1994.
139. Somberg J. To Begin Again. Editorial, *Amer J of Therap* 1(1):3, 1994.
140. Somberg J. Pharmacoeconomics: These Changing Times. (Editorial) *Amer J of Therap* 1(2):105-106, 1994.
141. Somberg J. Therapeutics, Clinical Pharmacology, Molecular Pharmacology: Have We Lost our Academic Way? (Editorial) *Amer J of Therap* 1(3):171-172, 1994.
142. Somberg J. The Basis of Pharmaceutical Approval. (Editorial) *Amer J of Therap* 1(4):253, 1994.
143. Khosla S, Somberg J. Clinical Therapeutic Conference. *Amer J of Therap* 1(1):86-92, 1994.
144. Khosla S, Somberg J. Clinical Therapeutic Conference. *Amer J of Therap* 1(4):333-338, 1994.

145. Kerin NZ, Somberg J. Proarrhythmia: Definition, risk factors, causes, treatment and controversies. *Am Heart J* 128:575-585, 1994.
146. Somberg J. Deferred Consent: Issues in Clinical Research. (Editorial) *Amer J of Therap* 2(1):1, 1995.
147. Somberg J. Dismantling the FDA. (Editorial) *Amer J of Therap* 2(2):79, 1995.
148. Somberg J. The Governmental Revolution. (Editorial) *Amer J of Therap* 2(3):157, 1995.
149. Somberg J. The Calcium Channel Blockers. (Editorial) *Amer T of Therap* 2(4):231-232, 1995.
150. Somberg J. Practice Guidelines, Consensus Conferences: The Pros and Cons. (Editorial) *Amer J of Therap* 2(5):301, 1995.
151. Somberg J. A New Virus and the Adequacy of Public Health Methods. (Editorial) *Amer J of Therap* 2(6):371, 1995.
152. Somberg J. Proarrhythmia or Arrhythmogenicity. (Editorial) *Amer J of Therap* 2(7):449, 1995.
153. Duggal C, Somberg J. Clinical Therapeutic Conference: Sudden Death in a Young Athlete. *Amer J of Therap* 2(8):581-585, 1995.
154. Somberg J. Smoking. (Editorial) *Amer J of Therap* 2(8):523, 1995.
155. Somberg J. Misoprostol and Eicosanoids: A New and Exciting Area of Therapeutics. (Editorial) *Amer J of Therap* 2(9):589, 1995.
156. Somberg J. Off Label indications. (Editorial) *Amer J of Therap* 2(10):737-738, 1995.
157. Somberg J. The Information Age and Therapeutics. (Editorial) *Amer J of Therap* 2(11):827, 1995.
158. Somberg J. The Promise of Chirality. (Editorial) *Amer J of Therap* 2(12):909-910, 1995.
159. Khosla S, Coutinho N, Megellas M, Mukherjee D, Somberg T. Can Nitroglycerin Convert Effort-Induced Angina in men into Silent Myocardial Ischemia? *Am J Cardiol* 76:337-339, 1995.
160. Khosla S, Somberg J. Successful Heart Failure Therapy is Effective Antiarrhythmic Therapy. *Am H J* 131:1048-1050, 1996 .
161. Somberg J. Inertia in Clinical Research. *Am J Therap* 3(1):1-2, 1996.
162. Somberg J. Revisiting Adverse Drug Reactions (Editorial). *Am J Therap* 3(2):99, 1996.

163. Somberg JC. Research in Emergency Care without Consent: New Proposed FDA Rules. *Lancet* 347(8999):475-476, 1996.
164. Somberg J. Nonphysician Prescribing (Editorial). *Am J Therap* 3(3):177, 1996
165. Somberg J. The Cancer Myth (Editorial). *Am J Therap* 3(4):259-260. 1996.
166. Somberg J. Smoking, Smoking Cessation, and Regulation (Editorial). *Am J Therap* 3(5):333, 1996.
167. Khosla S, Hentschel J, Somberg J. Smoking Cessation Strategies. *Am J Therap* 3(5):342-347, 1996.
168. Somberg J. Milestones of Clinical Pharmacology (Editorial). *Am J Therap* (6):411, 1996.
169. Somberg T. Changing the Regulatory Process (Editorial). *Am J Therap* 3(7):477, 1996.
170. Somberg J. Histamine and Antihistamines: Clinical Pharmacology for the Practicing Physician. *Am J Therap* 3(7):521-524, 1996.
171. Somberg J. The Commercialization of Research (Editorial). *Am J Therap* 3(8):551, 1996.
172. Somberg J. The FDA and Software (Editorial). *Am J Therap* 3(9):609, 1996
173. Somberg J, Ichkhan K. Clinical Therapeutic Conference: Therapeutic Considerations in Atrial Fibrillation Management. *Am J Therap* 3(9):658-660, 1996.
174. Somberg J. Rational Therapeutics: Dose Titration and Monotherapy in Clinical Practice (Editorial). *Am J Therap* 3(10):671, 1996.
175. Khosla S, Somberg JC. Gender Differences in Drug Therapy. *Am J Therap* 3(10):735-739, 1996.
176. Somberg J. The Therapeutics of Hypertensive Emergency (Editorial). *Am J Therap* 3(11):741, 1996.
177. Khosla S, Tarabey R, Megellas M, Somberg J. Approaches to Intravenous Nitroglycerin Therapy. *Am J Therap* 3(11):766-770, 1996.
176. Somberg J. The Year in Review (Editorial). *Am J Therap* 3(12):795, 1996.
179. Ichkhan K, Molnar J, Somberg J. Relation of Left Ventricular Mass and QT Dispersion in Patients with Systemic Hypertension. *Am J Cardiology* 79:508-511, 1997.
180. Molnar J, Rosenthal J, Weiss J, Somberg J. QT Interval Dispersion in Healthy Subjects and Survivors of Sudden Cardiac Death: Circadian variation in a Twenty-Four Hour Assessment. Accepted by *Am J Cardiol* 1997.
181. Tarabey R, Sukenik D, Molnar J, Somberg JC. The Effect of Intracoronary Balloon Inflation at PTCA on QT Dispersion. *Am Heart J* 1998; 1 35:519-22.



182. Sellers M, Kerin NZ, Kerin DS, Maciejko J, Somberg J. Wrestling with the Angel of Death: Proarrhythmia of Nonantiarrhythmic Medications: Fact or Fiction? *Am H J* 1996.
183. Wolf M, Moffat M, Ranade V, Somberg JC, Lehrer E, Mosnaim AD. Lithium, Hypercalcemia, and Arrhythmia. *J Clin Psychopharmacol*, 1998;18:5-6.
184. Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, sun Y, Rubie C, Hordt M, Toubin JA, Borggreffe M, Assmam G, Qu X, Somberg JC Breithardt G, Oberti C, Funkel T. KCNE1 Mutations Cause Jerrel and Lange Nielsen Syndrome. *Nat Genet* 17(3) 267-268, 1997.
185. Molnar J, Roenthal JE, Weiss JC, Somberg JC. QT interval Dispersion in Health Subjects and Survivors of Sudden Death, Circadian Variation in a 24 hour Assessment. *Am J Cardiol* 79(9) 1190-1193, 1997.
186. Clark CT, Rosenblatt R, Somberg JC. Neurocardiogenic Syncope with Addison's Disease. *Am J Ther* 5:328-31, 2000.
187. Somberg JC, Ranade VV. Bioavailability and Pharmacokinetics of Magnesium After Administration of Magnesium Salts. *Am J Thera* 8:345-357, 2001.
188. Yelamanchi VP, Molnar J, Ranade V, Somberg JC. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. *Am J Thera* 2,117-122, 2001.
189. Somberg, JC, Molnar J. QT dispersion is a valuable electrocardiographically derived index. *Am J Cardio* 2002, 89 (in press).
190. Somberg, JC, Ranade V. Rapid Determination of Partition Coefficients Between n-Octanol/Water for Cardiovascular Therapies. *Am J Thera*. 9, 19-24, 2002.
191. Somberg, JC, Bailin SJ, Haffajee CI, et al. Intravenous Lidocaine Versus Intravenous Amiodarone (in a New Aqueous Formulation) for Incessant Ventricular Tachycardia. *Am J Cardiol*, 90:853-859, 2002.
192. Somberg JC, Gallik DM, Singer I. Hemodynamic and Surface Electrocardiographic Effects of a New Aqueous Formulation of Intravenous Amiodarone. *Am J Cardiol*, 90:964-968, 2002.

**The following manuscripts are in preparation.**

1. ....  
.....  
.....
2. ....  
.....

3. ....
- 4  
.....  
.....
5. ....  
.....
6. ....  
.....
7. ....
8. ....
9.  
    .....  
.....
10. ....
11. ....  
.....
12.  
    .....  
.....
13. ....
14. ....
15. ....
16. ....
17. ....  
.....
18. ....
19. ....  
.....
20. ....  
.....
21. ....  
.....

22.

.....  
.....